Lymphocyte activation with localized pGL1-TNF-alpha gene therapy in a glioma model

Oncology

Volumn 62, Issue 1, 2002, Pages 66-77

  Gridley, Daila S ^a,b   Li, Jun ^b   Kajioka, Eric H ^a   Dutta Roy, Radha ^a   Andres, Melba L ^a   Timiryasova, Tatyana M ^b   Fodor, Istvan ^b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain tumor; C6 glioma; Lymphocytes; Radiation; TNF gene therapy

Indexed keywords

CD19 ANTIGEN; CD71 ANTIGEN; HEMOGLOBIN; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE COUNT; FLOW CYTOMETRY; GENE THERAPY; GLIOMA; HEMATOCRIT; LEUKOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFORMATION; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMA; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; SPLENOMEGALY; THROMBOCYTOPENIA; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; BODY WEIGHT; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLOW CYTOMETRY; GLIOMA; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; MICE; MICE, NUDE; MITOGENS; ORGAN SIZE; PLASMIDS; SPLEEN; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036164454     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048249     Document Type: Article

References (58)

1. Intracranial tumors in adults
2. Immune defects observed in patients with primary malignant brain tumors
3. Human gene therapy
4. Cationic lipid-mediated gene transfer
5. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid: pcDNA complexes
6. Genetic strategies for brain tumor therapy
7. Gene therapy for the treatment of brain tumors using interatumoral transduction with the thymidine kinase gene and intravenous ganciclovir
8. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system
9. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system
10. Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors
11. Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-α and herpes simplex virus thymidine kinase
12. Gene therapy for gliomas: Molecular targets, adenoviral vectors, and oncolytic adenoviruses
13. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene
14. The use of halogenated thymidine analogues as clinical radiosensitizers. Rationale, current status, and future prospects
15. Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor α for the treatment of malignant gliomas
16. Immune functions of tumor necrosis factor
17. A phase I trial of intravenously administration tumor necrosis factor-alpha in cancer patients
18. Phase I trial of recombinant human tumor necrosis factor-α in patients with advanced malignancy
19. Effects of tumor necrosis factor-α and radiation on human tumor xenografts
20. Evaluation of tumor necrosis factor-α and radiation efficacy in human lung adenocarcinoma model
21. Tumor necrosis factor-α enhances the anti-tumor effects of radiation against glioma xenografts
22. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy
23. Phase I dose-escalation study of tumor necrosis factor-α and concomitant radiation therapy
24. A model using radiation and plasmid-mediated tumor necrosis factor-β gene therapy for treatment of glioblastoma
25. Evaluation of pGL1-TNF-α therapy in combination with radiation
26. Differentiated rat glial cell strain in tissue culture
27. Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors
28. Enhancement of prostate cancer xenograft growth with whole-body radiation and vascular endothelial growth factor
29. Acute effects of whole-body proton irradiation on the immune system of the mouse
30. Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease
31. Tumor necrosis factor activation and cancer therapy - A perspective
32. Tumor necrosis factor-α induces p53-dependent apoptosis in rat glioma cells
33. Tumor necrosis factor-α (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature
34. Mechanisms of antitumor activity of tumor necrosis factor a with hyperthermia in a tumor necrosis factor α-resistant tumor
35. Ceramide and the induction of apoptosis
36. Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor
37. Differential augmentation by recombinant human tumor necrosis factor-α of neutrophil responses to particulate zymosan and glucan
38. Tumors secreting human TNF/cachectin induce cachexia in mice
39. Tumors producing human TNF induce hypercalcemia ad osteoclastic bone resorption in nude mice
40. Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma
41. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer
42. Tumor necrosis factor infusions have a procoagulant effect on the hemastatic mechanism of humans
43. Role of mast cells and monoamines in the thrombocytopaenia and mortality elicited by tumour necrosis factor in mice
44. VWF release and platelet aggregation in human melanoma after perfusion with TNFα
45. A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy
46. Protection from tumor necrosis factor-mediated cytolysis by platelets
47. Lysis of tumor cells by natural killer cells in mice is impeded by platelets
48. Role of TNF receptors I and II in TNF-induced platelet consumption in mice
49. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
50. Cytotoxicity and proliferation of splenocytes and lymph node cells from adjuvant-treated nude mice. Studies of natural and in vitro activation
51. Intravenous injection of naked DNA encoding secreted flt3 ligand dramatically increases the number of dendritic cells and natural killer cells in vivo
52. Growth inhibition of glioma cells by liposome-mediated cell transfection with tumor necrosis factor-alpha gene - Its enhancement by prior gamma-interferon treatment
53. Mouse cell surface antigens: Nomenclature and immunophenotyping
54. Radiation damage and immune suppression in splenic mononuclear cell populations
55. Signals and signs for lymphocyte responses
56. T cells. I. T-cell differentiation and function
57. Postthymic T-cell development
58. The potential biological and clinical significance of the soluble tumor necrosis factor receptors